Summary

Other Scenarios:

Buyer: Elan Corporation, plc (ADR) (ELN) Last Price: 19.74 Market Cap.: 9.31B
Target: Pharmion Corporation (PHRM) Last Price: 72.32 Market Cap.: 2.71B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 918
Biopharmaceuticals 375
Outsourced Services   66

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 17)
  • Tysabri (Natalizumab)
  • ELND001 (Alpha-4-Integrin Inhibitor)
  • ELND002 (Alpha-4-Integrin Inhibitor)
  • Autoimmune Research
Target (Total: 5)
  • Innohep (Tinzaparin Sodium)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  • Vidaza (Azacitidine)
Buyer
  • Contract Manufacturing Services
  • NanoSystems NanoCrystal Technology
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 6)
  • PDL BioPharma Inc. (PDLI)
  • Antigenics, Inc. (AGEN)
  • GTC Biotherapeutics, Inc. (GTCB)
  • Pharsight Corporation (PHST)
Target (Total: 6)
  • GPC Biotech AG (ADR) (GPCB)
  • Celgene Corporation (CELG)
  • salesforce.com, inc. (CRM)
  • MethylGene Inc. (MYG:CA)
Buyer (Total: 13)
  • AmerisourceBergen Corp. (ABC)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Cephalon, Inc. (CEPH)
Target (Total: 4)
  • US Oncology, Inc.
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Government - United Kingdom

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 1,610 513
Revenue Per Employee 543,850.3 558,770.6
Total Revenue 218.3 71.5
Total Expenses 262.2 102.6
Other Revenue 0.0 0.0
Cost of Revenue 97.2 19.7
SG&A Expense 79.8 50.0
Research & Development 82.0 30.4
Other Operating Expense 3.2 0.0
Operating Income -43.9 -31.2
Unusual Income 0.0 0.0
LT Debt to Capital 115.34 0
Fwd P/E -51.95 -395.28
Fwd P/Rev 9.50 7.21
Book Value -234.7 358.9
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Neurology

Target

Focused (): Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily areas, such as Alzheimer?s disease, Parkinson?s disease, multiple sclerosis (MS), Crohn?s disease (CD) and severe chronic pain. EDT is a specialty pharmaceutical business unit of Elan. Elan?s marketed products in the the United States include PRIALT (ziconotide intrathecal infusion), AZACTAM (aztreonam for injection, USP) and MAXIPIME (cefepime hydrochloride) for Injection. On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the United States Food and Drug Administration for the reintroduction of TYSABRI (natalizumab) as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.

Target

Pharmion Corporation is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. The Company has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram (Thalidomide Pharmion), a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma. In January 2008, Celgene Corporation has cleared its pending acquisition of Pharmion.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 55.5 72.66
Operating Margin % -37.41 -25.91
Quick Ratio 3.32 3.64
Current Ratio 4.35 4
Coverage Ratio 0.4 -0.15
Total Assets 1,781.4 443.3
Return on Equity % n/a -17.79
Return on Assets % -22.73 -14.4
Cash+ ST Inv. Per Share 1.49 6.67
Total Debt 1,765.0 0.0
Total Debt to Equity % 0 0
Total Debt to Tangible Equity % n/a 0
Debt to Asset % 99.08 0.00

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System  
Vascular Disorders  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Digestive System  
Gastrointestinal Tract Disorders  
Intestinal Disorders  
Inflammatory Bowel Disease (IBD)  
Crohn`s Disease  
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.

Buyer Products:

  • Tysabri (Natalizumab)
  
Hematology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  
White Blood Cell (WBC) Disorders  
Myelodysplastic Syndromes (MDS)  
Antimetabolite Agents  
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.

Target Products:

  • Vidaza (Azacitidine)
  
Immunology  
Autoimmune Disorders  
Inflammatory Bowel Disease (IBD)  
Crohn`s Disease  
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.

Buyer Products:

  • Tysabri (Natalizumab)
  
Multiple Sclerosis (MS)  
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.

Buyer Products:

  • Tysabri (Natalizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • ELND001 (Alpha-4-Integrin Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • ELND002 (Alpha-4-Integrin Inhibitor)
  • Autoimmune Research
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Maxipime (Cefepime Hydrochloride)
  
Monobactams
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.

Buyer Products:

  • Azactam (Aztreonam For Injection, USP)
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • ELND001 (Alpha-4-Integrin Inhibitor)
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Monoclonal Antibodies
Therapeutics that treat Alzheimer's Disease by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • AAB-001 (Bapineuzumab)
  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Alpha 4 Integrin Inhibitors
Therapeutics that prevent/inhibit the inflammation process by blocking the action of integrin, molecules involved in the inflammation process.

Buyer Products:

  • Tysabri (Natalizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AAB-001 (Bapineuzumab)
  • Bapineuzumab SubQ (Subcutaneous)
  • ELND005/AZD-103 (Anti-Amyloid Compound)
  • ACC-001 (A-beta Immunotherapeutic Conjugate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Parkinson's Disease Program
  • Beta-Secretase Inhibitors
  • AAB-002 (Monoclonal Antibody)
  • Gamma Secretase
  
Oncology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Vidaza (Azacitidine)
  • Oral Azacitidine
  
Respiratory System/Thoracic  
Lung Cancer  
Small Cell Lung Cancer (SCLC)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.

Target Products:

  • Amrubicin (Anthracycline)
  
Pain Management  
Non-Narcotics  
Calcium Channel Blocking Agents
Therapeutics that treat pain by blocking the movement of calcium ions and thus the initiation and conduction of nerve impulses across the neuronal membrane.

Buyer Products:

  • Prialt (Ziconotide)
  
Surgery  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Outsourced Services  
Development/Manufacturing Services  
Contract Manufacturing Organizations (CMO)  
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Buyer Products:

  • Contract Manufacturing Services
  
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.

Buyer Products:

  • Contract Manufacturing Services
  
Drug Delivery Technology  
Oral Delivery  
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.

Buyer Products:

  • NanoSystems NanoCrystal Technology
  
Parenteral/Injectable Delivery  
Polymer Based
Drug Delivery Technology used to deliver drugs using a polymer based matrix to hold/enclose the drug.

Buyer Products:

  • NanoSystems NanoCrystal Technology
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Buyer
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Bayer AG (ADR) n/a 54,726.881 7.55 14.14 1.19 1.27 n/a
Teva Pharmaceutical Industries Ltd (ADR) n/a 38,602.146 19.78 17.88 4.10 3.61 11.36
Biogen Idec Inc. n/a 16,733.583 26.26 17.48 5.28 4.58 8.79
Shire plc (ADR) n/a 11,013.064 0.00 19.66 4.52 3.82 n/a
MPS Group, Inc. n/a 1,039.114 11.93 12.11 0.48 0.45 3.49
Eurand N.V. n/a 591.051 0.00 35.29 4.54 3.65 n/a
Acorda Therapeutics Inc. n/a 534.710 0.00 -11.96 13.54 10.78 10.80
DURECT Corporation n/a 350.289 0.00 -14.88 11.42 11.63 12.51
Nymox Pharmaceutical Corporation n/a 158.814 0.00 n/a 418.63 n/a n/a
Javelin Pharmaceuticals Inc. n/a 142.073 0.00 -3.40 n/a 14.60 4.63
CytRx Corporation n/a 139.843 0.00 -7.50 19.40 n/a 3.23
Penwest Pharmaceuticals n/a 70.242 0.00 -2.11 22.12 24.05 3.30
Target
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
GlaxoSmithKline plc (ADR) n/a 115,986.006 11.18 10.85 2.57 2.53 15.20
sanofi-aventis (ADR) n/a 98,531.811 16.69 9.14 2.25 2.40 n/a
Genentech, Inc. n/a 83,607.511 30.19 25.16 7.13 6.43 9.13
Eli Lilly & Co. n/a 56,508.154 19.14 12.64 3.03 2.79 5.04
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Eisai Co., Ltd (ADR) n/a 9,661.528 13.56 13.89 1.46 1.40 2.29
Millennium Pharmaceuticals, Inc. n/a 4,249.041 284.76 58.61 8.05 7.65 5.90
SuperGen, Inc. n/a 135.648 10.37 -12.63 5.91 3.71 1.48
Poniard Pharmaceuticals, Inc. n/a 132.393 0.00 -3.07 n/a 12.14 1.53
Vion Pharmaceuticals, Inc. n/a 25.897 0.00 -0.71 1,194.74 n/a 3.14

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  PDL BioPharma Inc. n/a 1,303.381 0.00 15.70 2.81 3.21 n/a
Antigenics, Inc. n/a 108.893 0.00 -2.81 19.61 n/a n/a
GTC Biotherapeutics, Inc. n/a 49.147 0.00 n/a 3.60 3.11 61.48
Pharsight Corporation n/a 44.598 0.00 29.56 1.59 1.58 5.07
Vernalis plc (ADR) n/a 43.862 0.00 -1.21 1.09 1.40 n/a
AutoImmune Inc. n/a 31.412 0.00 n/a 88.10 n/a 3.55
Target
  GPC Biotech AG (ADR) 66.00% 123.561 0.00 -1.04 3.95 3.84 1.63
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
salesforce.com, inc. n/a 6,759.538 368.29 174.97 9.03 6.62 16.14
MethylGene Inc. n/a 87.304 0.00 n/a 6.00 n/a 1.75
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Cardinal Health, Inc. 16.00% 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation 11.00% 16,575.105 17.63 17.42 0.17 0.16 5.60
Buyer
  AmerisourceBergen Corp. 18.00% 6,687.985 14.64 14.03 0.10 0.10 n/a
Cardinal Health, Inc. 16.00% 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation 11.00% 16,575.105 17.63 17.42 0.17 0.16 5.60
Cephalon, Inc. n/a 4,072.540 0.00 13.67 2.30 2.16 527.26
Watson Pharmaceuticals, Inc. n/a 2,867.169 20.33 14.40 1.15 1.12 7.76
Sciele Pharma Inc. n/a 671.385 14.79 9.33 1.76 1.53 77.78
Acorda Therapeutics Inc. n/a 534.710 0.00 -11.96 13.54 10.78 10.80
Ligand Pharmaceuticals Inc. n/a 358.830 1.27 -40.11 27.83 n/a 8.65
EntreMed, Inc. n/a 68.079 0.00 n/a 9.21 n/a 2.55
Hana Biosciences, Inc. n/a 32.491 0.00 -0.96 28.22 21.91 2.07
Aeolus Pharmaceuticals, Inc. n/a 12.621 0.00 n/a n/a n/a 18.37
DOV Pharmaceutical, Inc. n/a 8.860 0.65 n/a 0.29 n/a 0.71
Government - United States n/a n/a n/a n/a n/a n/a n/a
Target
  US Oncology, Inc. 19.00% n/a n/a n/a n/a n/a n/a
Cardinal Health, Inc. 11.00% 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation 9.00% 16,575.105 17.63 17.42 0.17 0.16 5.60
Government - United Kingdom n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Roche Holding Ltd. (ADR) n/a 162,161.754 18.24 19.03 3.86 3.93 5.53
Novartis AG (ADR) n/a 108,444.656 9.08 13.48 2.78 2.71 3.88
sanofi-aventis (ADR) n/a 98,531.811 16.69 9.14 2.25 2.40 n/a
Abbott Laboratories n/a 78,894.465 21.88 16.18 3.04 2.85 40.89
Wyeth n/a 55,284.879 11.98 12.11 2.47 2.48 4.04
Biogen Idec Inc. n/a 16,733.583 26.26 17.48 5.28 4.58 8.79
Eisai Co., Ltd (ADR) n/a 9,661.528 13.56 13.89 1.46 1.40 2.29
Cephalon, Inc. n/a 4,072.540 0.00 13.67 2.30 2.16 527.26
Watson Pharmaceuticals, Inc. n/a 2,867.169 20.33 14.40 1.15 1.12 7.76
PDL BioPharma Inc. n/a 1,303.381 0.00 15.70 2.81 3.21 n/a
Sciele Pharma Inc. n/a 671.385 14.79 9.33 1.76 1.53 77.78
Exelixis, Inc. n/a 611.530 0.00 -3.96 5.39 5.25 72.83
Acorda Therapeutics Inc. n/a 534.710 0.00 -11.96 13.54 10.78 10.80
Target
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Cardinal Health, Inc. n/a 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation n/a 16,575.105 17.63 17.42 0.17 0.16 5.60
GPC Biotech AG (ADR) n/a 123.561 0.00 -1.04 3.95 3.84 1.63
MethylGene Inc. n/a 87.304 0.00 n/a 6.00 n/a 1.75
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
LEO Pharma A/S n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a
Dainippon Sumitomo Pharma Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Nippon Shinyaku Co., Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 759.4 267.3 1,026.7
Other Revenue 0.0 0.0 0.0
Total Revenue 759.4 267.3 1,026.7
Cost of Revenue 337.9 73.1 411.0
SG&A Expense 341.8 143.2 485.0
Depreciation & Amortization 0.0 9.9 9.9
Research & Development 260.4 102.4 362.8
Interest Expense 0.0 0.0 0.0
Other Operating Expense 84.6 0.0 84.6
Unusual Expense (Income) 18.8 8.0 26.8
Total Expenses 1,043.5 336.5 1,380.0
Operating Income -284.1 -69.2 -353.3
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -113.1 10.2 -102.9
Other, Net 0.0 0.0 0.0
Income Before Taxes -398.1 -59.1 -457.2
Income Taxes 6.9 4.8 11.7
Income After Taxes -405.0 -63.9 -468.9
Net Income - Excl. Xord. Items -405.0 -63.9 -468.9
Net Income - Incl. Xord. Items -405.0 -63.9 -468.9
Income Avail. to Common -405.0 -63.9 -468.9
Share Items
Basic Avg. Shares Outstanding 469.9 37.3 507.2
Basic EPS - Excl. Xord. Items n/a n/a -0.92
Basic EPS - Incl. Xord. Items n/a n/a -0.92
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 469.9 37.3 507.2
F.D. EPS - Excl. Xord. Items n/a n/a -0.92
F.D. EPS - Incl. Xord. Items n/a n/a -0.92
Balance Sheet
Assets
Cash and Equivalents 423.5 178.9 602.4
ST Investments 276.9 69.7 346.6
Accounts Receivable 0.0 45.0 45.0
Inventory 0.0 12.8 12.8
Prepayments and Advances 195.9 2.8 198.7
Other Current Assets 20.1 13.6 33.7
Current Assets 916.4 322.8 1,239.2
Accum D&A 0.0 0.0 0.0
PPE, Net 328.9 11.4 340.3
Goodwill & Intangibles 457.6 103.1 560.7
Long Term Investments 22.5 0.0 22.5
Other Assets 0.0 0.0 0.0
Other LT Assets 56.0 6.0 62.0
Total Assets 1,781.4 443.3 2,224.7
Liabilities
Accounts Payable 0.0 14.3 14.3
Payable/Accrued 207.6 0.0 207.6
Accrued Expenses 0.0 66.3 66.3
ST Debt 0.0 0.0 0.0
Other (Current) Liabilities 3.2 0.0 3.2
Current Liab. 210.8 80.6 291.4
LT Debt 1,765.0 0.0 1,765.0
Total LT Debt 1,765.0 0.0 1,765.0
Deferred Taxes 0.0 2.7 2.7
Other LT Liab. 40.3 1.1 41.4
Total Liabilities 2,016.1 84.4 2,100.5
Shareholders Equity
Common Stock 0.0 0.0 0.0
Additional Paid in Capital 0.0 631.7 631.7
Retained Earnings 0.0 -290.7 -290.7
Other Equity -234.7 17.9 -216.8
Total Equity -234.7 358.9 124.2
Total Liab. & Equity 1,781.4 443.3 2,224.7
Shares Outstanding 470.2 37.4 507.6
Cash Flow
Operating Cash Flow
CF Net Income 0.0 -63.9 -63.9
CF Depreciation 0.0 12.6 12.6
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items 0.0 3.2 3.2
Change in Working Capital -167.5 24.5 -143.0
Total Cash From Operating Activities -167.5 -23.5 -191.0
Investing Cash Flow (not calculated)
Capital Expenditures -28.6 -6.7 -35.3
Other Investing Cash Flows -289.5 8.6 -280.9
Total Cash From Investing Activities -318.1 1.8 -316.3
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 0.0 138.0 138.0
Purchase and Retirement of Debt 0.0 -0.9 -0.9
Other Financing Cash Flow -599.7 0.4 -599.3
Total Cash From Financing Activities -599.7 137.5 -462.2
Exchange Rate Effects -1.8 3.2 1.4
Net Change in Cash -1,087.1 119.0 -968.1
Cash Taxes Paid 5.2 3.0 8.2
Cash Interest Paid 169.2 0.2 169.4